REPLIGEN CORP Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
REPLIGEN CORP (RGEN) reported Research and Development Arrangement, Contract to Perform for Others, Compensation Earned of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned · last filed 2016-02-25
- REPLIGEN CORP research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2014-12-31 was $0.00.
- REPLIGEN CORP research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2014-06-30 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2014-03-31 was $0.00, a 100.00% decline year-over-year.
- REPLIGEN CORP research and development arrangement, contract to perform for others, compensation earned for fiscal 2015 was $0.00.
- REPLIGEN CORP research and development arrangement, contract to perform for others, compensation earned for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- REPLIGEN CORP research and development arrangement, contract to perform for others, compensation earned for fiscal 2013 was $803.00K, a 0.00% change from fiscal 2012.
- REPLIGEN CORP research and development arrangement, contract to perform for others, compensation earned for fiscal 2012 was $803.00K.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 3 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 6 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 9 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month as first filed |
|---|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-25 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $0.00 derived: sum of 2 quarters · filed 2016-02-25 | $0.00 derived: sum of 3 quarters · filed 2016-02-25 | $0.00 10-K · filed 2016-02-25 | |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | $0.00 10-Q · filed 2014-11-07 | -$678.00K derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | -$678.00K derived: sum of 3 quarters · filed 2016-02-25 | $41.00K derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-09 | -$678.00K derived: sum of 2 quarters · filed 2016-02-25 | $41.00K derived: sum of 3 quarters · filed 2016-02-25 | $183.00K derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-12-31 | -$678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $41.00K derived: sum of 2 quarters · filed 2016-02-25 | $183.00K derived: sum of 3 quarters · filed 2016-02-25 | $803.00K 10-K · filed 2016-02-25 | $1.59M 10-K · filed 2014-03-14 |
| 2013-09-30 | $719.00K 10-Q · filed 2014-11-07 | $861.00K derived: sum of 2 quarters · filed 2014-11-07 | $1.48M 10-Q · filed 2014-11-07 | $1.58M derived: sum of 4 quarters · filed 2015-03-17 | |
| 2013-06-30 | $142.00K 10-Q · filed 2014-08-11 | $762.00K 10-Q · filed 2014-08-11 | $862.00K derived: sum of 3 quarters · filed 2015-03-17 | $880.00K derived: sum of 4 quarters · filed 2015-03-17 | |
| 2013-03-31 | $621.00K 10-Q · filed 2014-05-09 | $720.00K derived: sum of 2 quarters · filed 2015-03-17 | $738.00K derived: sum of 3 quarters · filed 2015-03-17 | $1.02M derived: sum of 4 quarters · filed 2015-03-17 | |
| 2012-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-17 | $117.00K derived: sum of 2 quarters · filed 2015-03-17 | $402.00K derived: sum of 3 quarters · filed 2015-03-17 | $803.00K 10-K · filed 2015-03-17 | |
| 2012-09-30 | $18.00K 10-Q · filed 2013-11-08 | $303.00K derived: sum of 2 quarters · filed 2013-11-08 | $704.00K 10-Q · filed 2013-11-08 | ||
| 2012-06-30 | $285.00K 10-Q · filed 2013-08-07 | $686.00K 10-Q · filed 2013-08-07 | |||
| 2012-03-31 | $401.00K 10-Q · filed 2013-05-07 | ||||
| 2011-12-31 | $1.47M 10-K · filed 2014-03-14 | ||||
| 2011-09-30 | $100.00K 10-Q · filed 2012-11-08 | $623.00K derived: sum of 2 quarters · filed 2012-11-08 | $866.00K 10-Q · filed 2012-11-08 | ||
| 2011-06-30 | $523.00K 10-Q · filed 2012-08-09 | $766.00K 10-Q · filed 2012-08-09 | |||
| 2011-03-31 | $244.00K derived: 10-K 12 month − 10-K 9 month · filed 2013-03-15 | $1.35M 10-K · filed 2013-03-15 | |||
| 2010-12-31 | $1.10M 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |